Jong-Won Kim

Dr. Jong-Won Kim


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
KPKyoung-Jin Park
Kyoung-Jin Park
HPHyun-Kyung Park
Hyun-Kyung Park
YKYoung-Jin Kim
Young-Jin Kim
KLKyoung-Ryul Lee
Kyoung-Ryul Lee
JPJong-Ho Park
Jong-Ho Park
B.B.S.
B.S.
Kyoung-Jin Park, M.D., Hyun-Kyung Park, M.D., Young-Jin Kim, M.D., Kyoung-Ryul Lee, M.D., Jong-Ho Park, B.S., June-Hee Park, B.S., Hyung-Doo Park, M.D., Soo-Youn Lee, M.D., and Jong-Won Kim, M.D.. Ann Lab Med 2016;36:145-53. https://doi.org/10.3343/alm.2016.36.2.145

25 August 2021 in Genes
Verified
Journal Article
Open access
PDF file
CHChanghee Ha
Changhee Ha
JKJong-Won Kim
Jong-Won Kim
JJJa-Hyun Jang
Ja-Hyun Jang
Neurofibromatosis type 1, characterized by neurofibromas and café-au-lait macules, is one of the most common genetic disorders caused by pathogenic NF1 variants. Because of the high proportion of splicing mutations in NF1, identifying variants that alter splicing may be an essential issue for laboratories. Here, we investigated the sensitivity and specificity of SpliceAI, a recently introduced in silico splicing prediction algorithm in conjunction with other in silico tools. We evaluated 285 NF1 variants identified from 653 patients. The effect on variants on splicing alteration was confirmed by complementary DNA sequencing followed by genomic DNA sequencing. For in silico prediction of splicing effects, we used SpliceAI, MaxEntScan (MES), and Splice Site Finder-like (SSF). The sensitivity and specificity of SpliceAI were 94.5% and 94.3%, respectively, with a cut-off value of Δ Score > 0.22. The area under the curve of SpliceAI was 0.975 (p < 0.0001). Combined analysis of MES/SSF showed a sensitivity of 83.6% and specificity of 82.5%. The concordance rate between SpliceAI and MES/SSF was 84.2%. SpliceAI showed better performance for the prediction of splicing alteration for NF1 variants compared with MES/SSF. As a convenient web-based tool, SpliceAI may be helpful in clinical laboratories conducting DNA-based NF1 sequencing.

25 August 2011 in Human Genetics
Verified
Journal Article
Closed access
PDF file
MAMyung-Ju Ahn
Myung-Ju Ahn
HWHong-Hee Won
Hong-Hee Won
JLJeeyun Lee
Jeeyun Lee
SLSeung-Tae Lee
Seung-Tae Lee
JSJong-Mu Sun
Jong-Mu Sun
KPKeunchil Park
Keunchil Park

18 May 2011 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
NSNassr Eldin M. A. Shrif
Nassr Eldin M. A. Shrif
HWHong-Hee Won
Hong-Hee Won
SLSeung-Tae Lee
Seung-Tae Lee
JPJun-Hee Park
Jun-Hee Park
KKKa-Kyung Kim
Ka-Kyung Kim
JKJong-Won Kim
Jong-Won Kim
African populations, including the Sudanese, are underrepresented in warfarin pharmacogenetic studies. We designed a study to determine the associations between the polymorphisms and haplotype structures of CYP2C9 and VKORC1 and warfarin dose response in Sudanese patients, one of the most genetically diverse populations in Africa. The effect of the CYP2C9 polymorphisms (*2, *3, *5, *6, *8, *9, and *11), 20 VKORC1 tag SNPs and haplotypes, and clinical covariates were comprehensively assessed in 203 Sudanese warfarin-treated patients. Patients with the CYP2C9*2,*5,*6, or *11 variant required a daily warfarin dose that was 21% lower than those with CYP2C9*1/*1 (4.7 vs 5.8 mg/day, P < 0.001). SNPs around the VKORC1 and POL3S genes were divided into two haplotype blocks in Sudanese populations. According to multiple linear regression results, rs8050984, rs7294, and rs7199949 in the VKORC1 and POL3S genes (P <0.001, <0.001, <0.001, respectively), CYP2C9 genotype (*2, *5, *6, *11; P < 0.001), body weight (P = 0.04), target INR (P = 0.007), and concurrent medications (P = 0.029) could explain about 36.7% of the total warfarin dose variation. Our data revealed that VKORC1 and CYP2C9 polymorphisms are important factors that influence warfarin dose response in Sudanese patients. Our data suggest that combinations of the SNPs may improve predictions of warfarin dose requirements.

1 March 2022 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
SSSaeam Shin
Saeam Shin
HWHye In Woo
Hye In Woo
JKJong-Won Kim
Jong-Won Kim
YKYoonjung Kim
Yoonjung Kim
KLKyung-A Lee
Kyung-A Lee
Saeam Shin, M.D., Ph.D., Hye In Woo, M.D., Ph.D., Jong-Won Kim, M.D., Ph.D., Yoonjung Kim M.D., Ph.D., Kyung-A Lee, M.D., Ph.D.. Ann Lab Med 2022;42:141-9. https://doi.org/10.3343/alm.2022.42.2.141

18 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HKHee-Jin Kim
Hee-Jin Kim
HWHong-Hee Won
Hong-Hee Won
KPKyoung-Jin Park
Kyoung-Jin Park
SHSung Hwa Hong
Sung Hwa Hong
CKChang-Seok Ki
Chang-Seok Ki
JKJong-Won Kim
Jong-Won Kim
Autosomal dominant non-syndromic hearing loss (AD-NSHL) is one of the most common genetic diseases in human and is well-known for the considerable genetic heterogeneity. In this study, we utilized whole exome sequencing (WES) and linkage analysis for direct genetic diagnosis in AD-NSHL. The Korean family had typical AD-NSHL running over 6 generations. Linkage analysis was performed by using genome-wide single nucleotide polymorphism (SNP) chip and pinpointed a genomic region on 5q31 with a significant linkage signal. Sequential filtering of variants obtained from WES, application of the linkage region, bioinformatic analyses, and Sanger sequencing validation identified a novel missense mutation Arg326Lys (c.977G>A) in the POU homeodomain of the POU4F3 gene as the candidate disease-causing mutation in the family. POU4F3 is a known disease gene causing AD-HSLH (DFNA15) described in 5 unrelated families until now each with a unique mutation. Arg326Lys was the first missense mutation affecting the 3rd alpha helix of the POU homeodomain harboring a bipartite nuclear localization signal sequence. The phenotype findings in our family further supported previously noted intrafamilial and interfamilial variability of DFNA15. This study demonstrated that WES in combination with linkage analysis utilizing bi-allelic SNP markers successfully identified the disease locus and causative mutation in AD-NSHL.